178 related articles for article (PubMed ID: 26810896)
1. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
3. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
[TBL] [Abstract][Full Text] [Related]
5. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice.
Zhou PJ; Ma BB; He W; Xu D; Wang XH
J Immunother; 2011 Sep; 34(7):535-41. PubMed ID: 21760530
[TBL] [Abstract][Full Text] [Related]
7. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
8. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
[TBL] [Abstract][Full Text] [Related]
9. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
[TBL] [Abstract][Full Text] [Related]
10. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
11. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.
Spanò V; Pennati M; Parrino B; Carbone A; Montalbano A; Cilibrasi V; Zuco V; Lopergolo A; Cominetti D; Diana P; Cirrincione G; Barraja P; Zaffaroni N
J Med Chem; 2016 Aug; 59(15):7223-38. PubMed ID: 27428868
[TBL] [Abstract][Full Text] [Related]
13. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.
Sommariva M; de Cesare M; Meini A; Cataldo A; Zaffaroni N; Tagliabue E; Balsari A
J Transl Med; 2013 Jan; 11():25. PubMed ID: 23360557
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.
Du HY; Dong LH; Zhao BJ; Fu J; Wang QQ; Chen F; Ou L; Li N; Sun X; Tang ZM; Song HF
Acta Pharmacol Sin; 2012 Aug; 33(8):1047-54. PubMed ID: 22728711
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
18. Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.
Petrangolini G; Tortoreto M; Perego P; Carenini N; De Cesare M; Balsari A; Zunino F; Pratesi G
Cancer Biol Ther; 2008 Apr; 7(4):596-601. PubMed ID: 18364568
[TBL] [Abstract][Full Text] [Related]
19. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
20. CpG ODN 1826 enhances radiosensitivity of the human lung cancer cell line A549 in a rat model.
Yan W; Sun TY; Yang CM; Jia M; Li J; Tang HL; Zhou YF
Genet Mol Res; 2015 Aug; 14(3):9804-12. PubMed ID: 26345913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
